| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Invasive Fungal Infections | 23 | 2020 | 274 | 5.67 | Why? |
| Antifungal Agents | 36 | 2021 | 1828 | 5.66 | Why? |
| Triazoles | 15 | 2020 | 440 | 3.11 | Why? |
| Candidemia | 5 | 2019 | 353 | 2.46 | Why? |
| Nitriles | 11 | 2020 | 1053 | 2.18 | Why? |
| Invasive Pulmonary Aspergillosis | 8 | 2021 | 634 | 2.17 | Why? |
| Pyridines | 11 | 2020 | 680 | 2.03 | Why? |
| Pulmonary Aspergillosis | 9 | 2021 | 408 | 1.73 | Why? |
| Chemoprevention | 3 | 2018 | 585 | 1.49 | Why? |
| Vancomycin | 3 | 2019 | 328 | 1.33 | Why? |
| Aspergillus | 8 | 2021 | 347 | 1.32 | Why? |
| Clostridium Infections | 5 | 2019 | 595 | 1.19 | Why? |
| Candida | 7 | 2019 | 425 | 1.16 | Why? |
| Candidiasis, Invasive | 4 | 2018 | 107 | 1.12 | Why? |
| Voriconazole | 9 | 2021 | 206 | 1.00 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 526 | 0.94 | Why? |
| Echinocandins | 4 | 2018 | 139 | 0.88 | Why? |
| Mucormycosis | 7 | 2021 | 832 | 0.83 | Why? |
| Scedosporium | 1 | 2019 | 9 | 0.79 | Why? |
| Mucorales | 6 | 2019 | 92 | 0.77 | Why? |
| Mycoses | 4 | 2018 | 589 | 0.74 | Why? |
| Amphotericin B | 4 | 2020 | 256 | 0.74 | Why? |
| Diagnostic Tests, Routine | 3 | 2019 | 2643 | 0.73 | Why? |
| Myelodysplastic Syndromes | 2 | 2017 | 261 | 0.70 | Why? |
| CTLA-4 Antigen | 1 | 2019 | 282 | 0.67 | Why? |
| Guideline Adherence | 3 | 2019 | 2309 | 0.64 | Why? |
| Aspergillosis | 4 | 2018 | 264 | 0.60 | Why? |
| Disease Management | 6 | 2020 | 6841 | 0.58 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.58 | Why? |
| Heart Conduction System | 1 | 2018 | 266 | 0.56 | Why? |
| Immunocompromised Host | 11 | 2019 | 5150 | 0.54 | Why? |
| Leukemia, Myeloid, Acute | 2 | 2017 | 676 | 0.53 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2019 | 724 | 0.53 | Why? |
| Surgical Wound Infection | 1 | 2019 | 501 | 0.53 | Why? |
| Administration, Intravenous | 6 | 2018 | 1115 | 0.49 | Why? |
| Antibodies | 1 | 2019 | 846 | 0.47 | Why? |
| Practice Guidelines as Topic | 10 | 2021 | 15421 | 0.45 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.42 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.42 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.40 | Why? |
| Fluconazole | 3 | 2018 | 145 | 0.37 | Why? |
| Aspergillus fumigatus | 2 | 2021 | 239 | 0.36 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.36 | Why? |
| Fusarium | 2 | 2018 | 44 | 0.36 | Why? |
| Neutropenia | 4 | 2019 | 388 | 0.34 | Why? |
| Hematologic Neoplasms | 2 | 2021 | 2105 | 0.32 | Why? |
| Lung Diseases, Fungal | 2 | 2018 | 167 | 0.31 | Why? |
| Endophthalmitis | 2 | 2017 | 105 | 0.31 | Why? |
| Fungi | 6 | 2020 | 471 | 0.31 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.30 | Why? |
| Antimicrobial Stewardship | 3 | 2018 | 931 | 0.29 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.29 | Why? |
| Galactose | 3 | 2020 | 201 | 0.29 | Why? |
| Mannans | 3 | 2020 | 218 | 0.27 | Why? |
| Treatment Outcome | 14 | 2019 | 51732 | 0.24 | Why? |
| Humans | 78 | 2021 | 930598 | 0.24 | Why? |
| Administration, Oral | 3 | 2018 | 2340 | 0.24 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 4 | 2019 | 1261 | 0.22 | Why? |
| Central Nervous System Fungal Infections | 1 | 2020 | 17 | 0.21 | Why? |
| Recurrence | 3 | 2019 | 3675 | 0.20 | Why? |
| Drug Resistance, Fungal | 2 | 2020 | 191 | 0.20 | Why? |
| Ribotyping | 1 | 2019 | 54 | 0.20 | Why? |
| Aged, 80 and over | 15 | 2021 | 88759 | 0.20 | Why? |
| Oxazolidinones | 1 | 2019 | 49 | 0.19 | Why? |
| Microbial Sensitivity Tests | 5 | 2021 | 2886 | 0.19 | Why? |
| Aged | 29 | 2021 | 215776 | 0.19 | Why? |
| Middle Aged | 36 | 2021 | 270681 | 0.19 | Why? |
| Europe | 5 | 2018 | 12702 | 0.19 | Why? |
| Infection Control | 4 | 2020 | 23131 | 0.18 | Why? |
| Dopamine | 1 | 2018 | 123 | 0.18 | Why? |
| Survival Analysis | 4 | 2020 | 7592 | 0.18 | Why? |
| Male | 37 | 2021 | 367725 | 0.18 | Why? |
| Fusariosis | 1 | 2017 | 14 | 0.18 | Why? |
| Ascomycota | 1 | 2018 | 71 | 0.17 | Why? |
| Geotrichosis | 1 | 2017 | 3 | 0.17 | Why? |
| Geotrichum | 1 | 2017 | 3 | 0.17 | Why? |
| Placebos | 2 | 2019 | 629 | 0.17 | Why? |
| CARD Signaling Adaptor Proteins | 1 | 2017 | 70 | 0.17 | Why? |
| Intensive Care Units | 7 | 2021 | 29594 | 0.17 | Why? |
| Drug Resistance, Multiple, Fungal | 1 | 2017 | 45 | 0.17 | Why? |
| Antibodies, Fungal | 1 | 2017 | 49 | 0.17 | Why? |
| Female | 35 | 2021 | 380317 | 0.17 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2017 | 93 | 0.17 | Why? |
| Food Preferences | 1 | 2018 | 128 | 0.17 | Why? |
| RNA Splicing | 1 | 2017 | 119 | 0.16 | Why? |
| Bandages | 1 | 2018 | 109 | 0.16 | Why? |
| Medical Audit | 1 | 2018 | 218 | 0.16 | Why? |
| Adult | 30 | 2021 | 244371 | 0.16 | Why? |
| Induction Chemotherapy | 1 | 2017 | 149 | 0.16 | Why? |
| Herpes Zoster Vaccine | 1 | 2018 | 112 | 0.16 | Why? |
| Rare Diseases | 2 | 2018 | 373 | 0.16 | Why? |
| Intraabdominal Infections | 1 | 2017 | 90 | 0.16 | Why? |
| Bronchoalveolar Lavage Fluid | 4 | 2020 | 2309 | 0.16 | Why? |
| beta-Glucans | 1 | 2018 | 176 | 0.16 | Why? |
| Chlorhexidine | 1 | 2018 | 176 | 0.16 | Why? |
| Saccharomycetales | 1 | 2017 | 118 | 0.16 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.16 | Why? |
| Anti-Infective Agents | 2 | 2019 | 1766 | 0.16 | Why? |
| Keratitis | 1 | 2017 | 102 | 0.16 | Why? |
| Double-Blind Method | 5 | 2019 | 5988 | 0.15 | Why? |
| Bacteriological Techniques | 1 | 2018 | 239 | 0.15 | Why? |
| Central Venous Catheters | 1 | 2018 | 188 | 0.15 | Why? |
| Lumbar Vertebrae | 1 | 2017 | 196 | 0.15 | Why? |
| Eating | 1 | 2018 | 395 | 0.15 | Why? |
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 2426 | 0.15 | Why? |
| South America | 1 | 2017 | 565 | 0.15 | Why? |
| Unnecessary Procedures | 1 | 2017 | 175 | 0.14 | Why? |
| Societies, Scientific | 1 | 2018 | 414 | 0.14 | Why? |
| Graft vs Host Disease | 1 | 2019 | 501 | 0.14 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2020 | 760 | 0.14 | Why? |
| Hematology | 2 | 2021 | 649 | 0.14 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2020 | 4545 | 0.14 | Why? |
| Rhinovirus | 1 | 2020 | 979 | 0.14 | Why? |
| Young Adult | 15 | 2020 | 93724 | 0.14 | Why? |
| Evidence-Based Practice | 1 | 2020 | 693 | 0.14 | Why? |
| Endocarditis, Bacterial | 1 | 2019 | 344 | 0.14 | Why? |
| Endemic Diseases | 1 | 2018 | 480 | 0.13 | Why? |
| Germany | 8 | 2021 | 9196 | 0.13 | Why? |
| Endocarditis | 1 | 2019 | 368 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.13 | Why? |
| Candidiasis | 1 | 2018 | 334 | 0.13 | Why? |
| Taste | 1 | 2018 | 715 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.13 | Why? |
| Antineoplastic Agents | 2 | 2020 | 3550 | 0.13 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.13 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2019 | 10649 | 0.13 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.12 | Why? |
| Cornea | 1 | 2017 | 410 | 0.12 | Why? |
| Quality Indicators, Health Care | 1 | 2018 | 580 | 0.12 | Why? |
| Herpes Zoster | 1 | 2018 | 331 | 0.12 | Why? |
| Metapneumovirus | 2 | 2020 | 465 | 0.12 | Why? |
| Bronchoscopy | 1 | 2020 | 991 | 0.12 | Why? |
| Molecular Diagnostic Techniques | 2 | 2019 | 4239 | 0.12 | Why? |
| Paramyxoviridae Infections | 2 | 2020 | 364 | 0.12 | Why? |
| Hematologic Diseases | 1 | 2018 | 614 | 0.11 | Why? |
| Patient Care | 2 | 2020 | 1664 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.11 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2019 | 1387 | 0.11 | Why? |
| Anti-Infective Agents, Local | 1 | 2018 | 520 | 0.11 | Why? |
| Neoplasms | 4 | 2021 | 17251 | 0.11 | Why? |
| Vaccination Coverage | 1 | 2020 | 1249 | 0.11 | Why? |
| Sepsis | 2 | 2018 | 3517 | 0.11 | Why? |
| Registries | 4 | 2021 | 12327 | 0.11 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.11 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.11 | Why? |
| T-Lymphocytes | 2 | 2019 | 6670 | 0.11 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.10 | Why? |
| Global Health | 4 | 2017 | 13911 | 0.10 | Why? |
| Biopsy | 1 | 2019 | 2811 | 0.10 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.10 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.10 | Why? |
| Bocavirus | 1 | 2009 | 74 | 0.10 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.10 | Why? |
| Genomics | 1 | 2021 | 3118 | 0.09 | Why? |
| Consensus | 2 | 2021 | 6345 | 0.09 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| DNA, Fungal | 2 | 2018 | 95 | 0.09 | Why? |
| CD40 Ligand | 2 | 2019 | 121 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Societies, Medical | 3 | 2021 | 6907 | 0.09 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.09 | Why? |
| Immunization Programs | 1 | 2020 | 2006 | 0.09 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.08 | Why? |
| Adolescent | 10 | 2020 | 86841 | 0.08 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.08 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.08 | Why? |
| Parvoviridae Infections | 1 | 2009 | 222 | 0.08 | Why? |
| England | 1 | 2018 | 5116 | 0.08 | Why? |
| Clinical Trials, Phase III as Topic | 2 | 2020 | 782 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2019 | 6551 | 0.07 | Why? |
| Medical Oncology | 2 | 2021 | 3826 | 0.07 | Why? |
| Feces | 1 | 2019 | 4235 | 0.07 | Why? |
| Triage | 2 | 2021 | 7151 | 0.07 | Why? |
| Disinfection | 1 | 2018 | 2912 | 0.07 | Why? |
| Time-to-Treatment | 2 | 2018 | 5883 | 0.07 | Why? |
| Pneumonia, Pneumocystis | 1 | 2009 | 322 | 0.07 | Why? |
| Influenza Vaccines | 1 | 2020 | 2941 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Critical Illness | 2 | 2019 | 17281 | 0.07 | Why? |
| Organ Transplantation | 1 | 2019 | 2616 | 0.06 | Why? |
| Electrocardiography | 1 | 2018 | 3957 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.06 | Why? |
| Health Promotion | 1 | 2017 | 2020 | 0.06 | Why? |
| Internet | 1 | 2021 | 6204 | 0.06 | Why? |
| Communicable Diseases, Emerging | 1 | 2017 | 2523 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Animals | 6 | 2019 | 78931 | 0.06 | Why? |
| Viral Proteins | 1 | 2021 | 7370 | 0.06 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.06 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.06 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.06 | Why? |
| Secondary Metabolism | 1 | 2021 | 61 | 0.06 | Why? |
| Multicenter Studies as Topic | 2 | 2019 | 2437 | 0.06 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.06 | Why? |
| Brain | 1 | 2018 | 5133 | 0.06 | Why? |
| T-Cell Antigen Receptor Specificity | 1 | 2020 | 93 | 0.05 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.05 | Why? |
| Matched-Pair Analysis | 1 | 2019 | 83 | 0.05 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.05 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.05 | Why? |
| Flow Cytometry | 2 | 2019 | 2393 | 0.05 | Why? |
| Azoles | 1 | 2020 | 185 | 0.05 | Why? |
| Medical History Taking | 1 | 2021 | 350 | 0.05 | Why? |
| Cost Savings | 1 | 2021 | 296 | 0.05 | Why? |
| Enterococcus faecalis | 1 | 2019 | 126 | 0.05 | Why? |
| Antigens, Differentiation, T-Lymphocyte | 1 | 2019 | 146 | 0.05 | Why? |
| Mycology | 1 | 2018 | 37 | 0.05 | Why? |
| Influenza, Human | 2 | 2020 | 10779 | 0.05 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.05 | Why? |
| Reproducibility of Results | 3 | 2021 | 11304 | 0.05 | Why? |
| Natamycin | 1 | 2017 | 12 | 0.04 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.04 | Why? |
| Burkitt Lymphoma | 1 | 2017 | 15 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Mycological Typing Techniques | 1 | 2017 | 38 | 0.04 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.04 | Why? |
| Discitis | 1 | 2017 | 23 | 0.04 | Why? |
| Infectious Disease Medicine | 1 | 2021 | 311 | 0.04 | Why? |
| Proteoglycans | 1 | 2018 | 130 | 0.04 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.04 | Why? |
| Fungal Proteins | 1 | 2018 | 133 | 0.04 | Why? |
| Drug Compounding | 1 | 2019 | 386 | 0.04 | Why? |
| Naphthalenes | 1 | 2017 | 94 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Transplantation, Autologous | 1 | 2018 | 364 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.04 | Why? |
| Antibody Specificity | 1 | 2021 | 1328 | 0.04 | Why? |
| Fungemia | 1 | 2017 | 86 | 0.04 | Why? |
| Lectins, C-Type | 1 | 2019 | 405 | 0.04 | Why? |
| Candida albicans | 1 | 2017 | 217 | 0.04 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 581 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Contact Lenses | 1 | 2017 | 108 | 0.04 | Why? |
| Osteomyelitis | 1 | 2017 | 131 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.04 | Why? |
| Metabolomics | 1 | 2021 | 921 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.04 | Why? |
| Monte Carlo Method | 1 | 2017 | 577 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Inflammasomes | 1 | 2021 | 710 | 0.03 | Why? |
| Lipopeptides | 1 | 2017 | 229 | 0.03 | Why? |
| Computer Simulation | 2 | 2020 | 4982 | 0.03 | Why? |
| Virulence | 1 | 2021 | 2172 | 0.03 | Why? |
| Influenza A virus | 2 | 2020 | 2234 | 0.03 | Why? |
| Antigens, CD | 1 | 2019 | 984 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.03 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.03 | Why? |
| Leukemia | 1 | 2018 | 598 | 0.03 | Why? |
| Lymphoma | 1 | 2018 | 522 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Tertiary Care Centers | 2 | 2021 | 8248 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| California | 1 | 2018 | 2047 | 0.03 | Why? |
| Nigeria | 1 | 2018 | 2292 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Vaccines, Inactivated | 1 | 2018 | 1562 | 0.03 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.03 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.03 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.03 | Why? |
| Environmental Exposure | 1 | 2020 | 1558 | 0.02 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.02 | Why? |
| Smartphone | 1 | 2021 | 1840 | 0.02 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.02 | Why? |
| Ambulatory Care Facilities | 1 | 2021 | 2063 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Macrophages | 1 | 2021 | 2784 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Multiple Myeloma | 1 | 2018 | 1064 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Patient Readmission | 1 | 2017 | 1543 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2021 | 3607 | 0.02 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.02 | Why? |
| Hemorrhage | 1 | 2020 | 3013 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.02 | Why? |
| Pneumocystis carinii | 1 | 2009 | 205 | 0.02 | Why? |
| Diarrhea | 1 | 2019 | 2743 | 0.02 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Child | 3 | 2020 | 70012 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Leadership | 1 | 2018 | 2241 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.02 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.02 | Why? |
| Travel | 1 | 2021 | 7220 | 0.01 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Radiography, Thoracic | 1 | 2018 | 5486 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Infant, Newborn | 1 | 2019 | 23105 | 0.01 | Why? |
| Infant | 1 | 2019 | 30274 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Prevalence | 1 | 2009 | 25773 | 0.00 | Why? |